Cell banking market is expected to grow at an exponential rate in the coming years owing to the growing demand for biologics. Overall, biologics are slowly taking a major share of the pharmaceutical market by means of stem cell therapies, monoclonal antibodies etc. Presently, USA takes the lead in terms of the cell line development market followed closely by Europe and Asia, However, as per the current scenario; APAC market is slowly gaining pace on par with the European market and is expected to surpass the market in the future. Across APAC, India is the leading market with respect to the stem cell banks. This is mainly due to the growing population in the country and a higher growth rate.
Relevance
The biotechnology space faced a reduction in bio-projects due to the lack of investments between 2010 and 2012. However, after 2013, there was a change in trend and even in the current scenario of 2015-17, more vested investments by pharma and biotechnology companies are taking place due to the demand for biologics, and due to successes in gene therapy and cellular therapy. Cell culture/ cell banking requirements are not only increasing in magnitude but also slowly shifting towards increased use of mammalian cell lines.
Biopharma production is further increasing through novel therapeutics as well as biosimilars. Process of biologics manufacturing and role of cell banks – The first step in biologics manufacturing is insertion of target genes in an expression vector (plasmid) which is known as inoculum development. The expression vector is then added to the genetically modified host cell expressing the protein of interest, which is cell culturing. After proteins have been collected and cultivated, a cell bank is created for future use. The downstream steps include harvesting the protein, followed by production recovery and isolation. The last step in downstream involves purification of proteins, that includes virus inactivation / removal, chromatography, and filtration. The final stage involves filling, finishing, packaging and storage, quality assurance and characterisation, and stability testing of the protein drug. In the described above, cell banks acts as one of the major components of biologics manufacturing and key to the large scale manufacturing of biologics drug. Also, Cell based bioassays are used during the evaluation of product potency, pharmacokinetic and pharmacodynamics properties, comparability and stability testing. The cell serves as a critical and complex reagent during the analytical test assay, hence requiring distinct characterization and control measures to guarantee the operational consistency. Bioassays are responsible for providing accurate information throughout the product under development and on the market.
Precisely, such accuracy and reliability of cell based bioassay test results are strictly associated with controlled, consistent banks of designated cells.
Global market
Globally cell banking markets expected to generate over $ 5 billion by 2020. Master cell banks are expected to accounts for major sharefollowed by Working and viral cell banks.North America dominates the market share but Asia-Pacific expected to witness high growth in next 7-10 years. United States is one of the key markets for cell line development and cell banking. USA currently leads the market with some of the key players such as QuintilesIms, BioReliance and Charles River. Most companies in the US have expertise in providing end-to-end services to the customers.Some of thesecompanies have also extended their facilities in the APAC region to increase their global presence. European region stands second in the global cell banking market closely following the US. Key players in Europe include Lonza Group, CMC biologics and Biorelience. APAC region has shown a remarkable growth in the cell banking market in the past few years. Major players of the industry are expanding their bases in APAC region so as to extend their global presence.Further to this, more and more CMOs are also currently focusing on these nations. The primary reason for an increased outsourcing to APAC region is lower cost of production which makes these locations ideal for production of large quantities of cell cultures.As a result, Asian markets hold a strong promise of establishing itself as the highest cell line and cell banking mark...
(All Rights Reserved)